AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Go back to AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042| ALLIANCEBERNSTEIN HOLDING, L.P. (NYSE: AB) | Delayed: 37.08 -0.07 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.15 | 52 Week High | $26.24 | |||
| Open | $37.04 | 52 Week Low | $16.11 | |||
| Day High | $37.15 | P/E | 21.81 | |||
| Day Low | $36.91 | EPS | $1.70 | |||
| Volume | 117,920 | |||||
